Floatz logo

Fluciclatide

Uterine Cancer

National Cancer Institute (NCI)protein_peptidePhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
89/ 100

Competitive context

47 Active assets in the Uterine Cancer cohort.

Asset / SponsorPhaseRating
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Gynecologic Oncology Associates
Phase 4BB
Ferrous Fumarate
Sunnybrook Health Sciences Centre
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
University of California, Irvine
Phase 3B
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Durvalumab
Mary Crowley Medical Research Center
Phase 2B

View all 50 →

Same molecule, other indications

Fluciclatide is also rated in:

malignant gliomaDormant
CCC
Indicative ·
50 / 100
View asset →
head and neck cancerDormant
CCC
Indicative ·
50 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →